Obesity, non-alcoholic fatty liver disease, and FTO oligonucleotide polymorphism


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim of the study: to determine the prevalence of FTO gene polymorphism and clinical importance of it in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity. Material and methods. 114 patients with NAFLD associated with obesity or overweight were examined. The comparison group consisted of 72 healthy individuals with a BMI <25, comparable to the patients by gender and age. Oligonucleotide polymorphism T / A of the FTO gene (rs9939609) was determined using allele-specific PCR (OOO NPF Litekh) followed by electrophoretic detection. Results. In patients with NAFLD associated with overweight and obesity, the FTO (rs9939609) T / A polymorphism was more often than in the healthy population. The AA genotype and the A allele in obesity of the 2 and 3 classes are more often, and the TT genotype is less often than in persons with class 1 obesity and overweight. Unfavorable genotypes of the FTO gene TA and AA were associated with high blood triglycerides. In patients with NAFLD with type 2 diabetes, allele A is more often observed and, less often, the TT genotype. The development of non-alcoholic steatohepatitis often occurs in the presence of the A allele of the FTO gene. Conclusion. The studies carried out indicate the important role of the FTO (rs9939609) T/A gene polymorphism in the pathogenesis of obesity and non-alcoholic fatty liver disease.

Full Text

Restricted Access

About the authors

Tatiana V. Geyvandova

Stavropol Regional Clinical Consultative and Diagnostic Center; Stavropol State Medical University of the Ministry of Healthcare of Russia

endocrinologist of Stavropol Regional Clinical Consultative and Diagnostic Center, applicant at the Department of hospital therapy

Sophia Sh. Rogova

Stavropol State Medical University of the Ministry of Healthcare of Russia

PhD, associate professor of the Department of clinical laboratory diagnostics with a course of bacteriology

References

  1. World Health Organization. Obesity and overweight. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (date of access - 01.08.2021).
  2. Weib J., Rau M., Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment. Dtsch Arztebl Int. 2014; 111(26): 447-52. doi: 10.3238/arztebl.2014.0447.
  3. Chen T.-P., Lai M., Lin W.-Y. et al. Metabolic profiles and fibrosis of nonalcoholic fatty liver disease in the elderly: A community-based study. J. Gastroenterol Hepatol. 2020; 35(9): 1636-43. doi: 10.1111/jgh.15073.
  4. Ивашкин В.Т., Драпкина О.М., Маев И.В. с соавт. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 6: 31-41.
  5. Guerrero R., Vega G.L., Grundy S.M., Browning J.D. Ethnic differences in hepatic steatosis: An insulin resistance paradox? Hepatology. 2009; 49(3): 791-801. doi: 10.1002/hep.22726.
  6. Makkonen J., Pietilainen K.H., Rissanen A. et al. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J. Hepatol. 2009; 50(5): 1035-42. doi: 10.1016/j. jhep.2008.12.025.
  7. Schwimmer J.B., Celedon M.A., Lavine J.E. et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009; 136(5): 1585-92. doi: 10.1053/j.gastro.2009.01.050.
  8. Browning J.D., Szczepaniak L.S., Dobbins R. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-95. doi: 10.1002/hep.20466.
  9. Ахмедов В.А., Меликов Т.И. Генетические аспекты формирования неалкогольной жировой болезни печени. Лечащий врач. 2019; 8: 28-31. doi: https://doi.org/10.26295/0S.2019.70.74.004.
  10. Dongiovanni P., Romeo S., Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int. 2015; 2015: 460190.doi: 0.1155/2015/460190.
  11. Gerken T., Girard C.A., Tung Y.C. et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007; 318(5855): 1469-72. doi: 10.1126/science.1151710.
  12. Hertel J.K., Johansson S., Sonestedt E. et al. FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. Diabetes. 2011: 60(5): 1637-44. doi: 10.2337/db10-1340.
  13. Fawwad A., Siddiqui I.A., Basit A. et al. Common variant within the FTO gene, rs9939609, obesity and type 2 diabetes in population of Karachi, Pakistan. Diabetes Metab Syndr. 2016; 10(1): 43-47. doi: 10.1016/j.dsx.2015.02.001.
  14. Do R., Bailey S.D., Desbiens K. et al. Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study. Diabetes. 2008; 57(4): 1147-50. doi: 10.2337/db07-1267.
  15. Хромова Н.В., Ротарь О.П., Ерина А.М. с соавт. Взаимосвязь rs9939609 полиморфизма гена FTO с метаболическим синдромом и его компонентами в российской популяции. Артериальная гипертензия. 2013; 4: 311-319. doi: https://doi.org/10.18705/1607-419X-2013-19-4-311-319.
  16. Насибулина Э.С., Шагимарданова Р.Р., Борисова А.В., Ахметов И.И. Ассоциация полиморфизма гена FTO с избыточной массой тела в российской популяции. Казанский медицинский журнал. 2012; 5: 823-826. doi: https://doi.org/10.17816/KMJ1720.
  17. Guo J., Ren W., Li X. et al. Altering of FTO in the serum and livers of NAFLD patients: A correlation analysis. Int J. Clin Exp Med. 2018; 11: 6046-53. ISSN: 1940-5901/IJCEM0028249.
  18. Lim A., Zhou J., Sinha R.A. et al. Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity. Biochem Biophys Res Commun. 2016; 479(3): 476-81. doi: 10.1016/j.bbrc.2016.09.086.
  19. Kang H., Zhang Z., Yu L. et al. FTO reduces mitochondria and promotes hepatic fat accumulation through RNA demethylation. J. Cell Biochem. 2018; 119(7): 5676-85. doi: 10.1002/jcb.26746.
  20. Chen X., Gao Y., Yang X. et al. Relationship of FTO gene variations with NAFLD risk in Chinese men. Open Life Sci. 2020; 15(1): 860-67. doi: 10.1515/biol-2020-0081.
  21. Батурин А.К., Сорокина Е.Ю., Погожева А.В. с соавт. Изучение ассоциации полиморфизмов rs993609 гена fto и rs659366 гена UCP2 с ожирением у населения Арктической зоны Российской Федерации. Вопросы питания. 2017; 3: 32-39. doi: https://dx.doi.org/10.24411/0042-8833-2017-00042.
  22. Nunez-Torres R., Macias J., Rivero-Juarez A. et al. Group for the Study of Viral Hepatitis (HEPAVIR) of the Andalusian Society of Infectious Diseases (SAEI). Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. HIV Med. 2017; 18(8): 546-54. doi: 10.1111/hiv.12489.
  23. Mizuno T.M. Fat mass and obesity associated (FTO) gene and hepatic glucose and lipid metabolism. Nutrients. 2018; 10(11): 1600. doi: 10.3390/nu10111600.
  24. Sabarneh A., Ereqat S., Cauchi S. et al. Common FTO rs9939609 variant and risk of type 2 diabetes in Palestine. BMC Med Genet. 2018; 19(1): 156. doi: 10.1186/s12881-018-0668-8
  25. Younus L.A., Algenabi A.H.A., Abdul-Zhara M.S., Hussein M.K. FTO gene polymorphisms (rs9939609 and rs17817449) as predictors of type 2 diabetes mellitus in obese Iraqi population. Gene. 2017; 627: 79-84. doi: 10.1016/j.gene.2017.06.005.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies